Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
MAIA - MAIA Biotechnology, Inc.
Market Cap 29.84M P/E - EPS this Y -6.00% Ern Qtrly Grth -
Income -19.77M Forward P/E -1.35 EPS next Y - 50D Avg Chg -4.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -33.00%
Dividend N/A Price/Book 4.74 EPS next 5Y - 52W High Chg -63.00%
Recommedations 2.00 Quick Ratio 1.48 Shares Outstanding 20.58M 52W Low Chg 6.00%
Insider Own 21.09% ROA -128.79% Shares Float 14.70M Beta -
Inst Own 3.79% ROE -440.12% Shares Shorted/Prior 785.18K/508.51K Price 2.19
Gross Margin - Profit Margin - Avg. Volume 32,988 Target Price 12.63
Oper. Margin - Earnings Date - Volume 30,997 Change 0.00%
Healthcare | Biotechnology | United States
About MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

MAIA Biotechnology, Inc. News
04/23/24 MAIA Biotechnology Announces $1.00 Million Private Placement
04/05/24 MAIA Biotechnology to Present at Two Investor Conferences in April 2024
03/28/24 MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero
03/26/24 MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement
03/26/24 MAIA Biotechnology Announces $1.33 Million Private Placement
03/22/24 MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement
03/21/24 MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board
03/16/24 Director Ngar Louie Acquires 170,940 Shares of MAIA Biotechnology Inc (MAIA)
03/07/24 MAIA Biotechnology to Participate in the 36th Annual ROTH Conference
03/06/24 MAIA Biotechnology and Nationwide Children’s Hospital Announce Presentation of THIO’s Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting
03/06/24 MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients
03/05/24 MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders
10:30 AM MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor
02/22/24 MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
02/07/24 MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer
01/24/24 MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds
01/18/24 MAIA Soars 20% on Interim Results From Lung Cancer Study
01/17/24 MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024
01/05/24 MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024
12/19/23 MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
MAIA Chatroom

User Image Vilvi Posted - 2 hours ago

$MAIA There is a reason why Vlad is pushing so much on the DCR. From one or their press release, they cited that <<DCR is far stronger than overall response rate (ORR) in predicting overall survival benefit, as shown in recent meta-analysis of 74 clinical trials worldwide >> (https://ir.maiabiotech.com/news-events/press-releases/detail/80/maia-biotechnology-announces-100-disease-control-in) The study analyzed the correlation of between the DCR and OS and compared it with the correlation between the ORR and OS. I won't go in details since it's out of my expertise and I might make some mistakes but for some of you who are more experienced you can find that study in the link bellow. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182707/

User Image LabPsycho Posted - 2 hours ago

$MAIA Post an article trying to stimulate spirited discussion and one gets high quality replies like this instead

User Image LabPsycho Posted - 2 hours ago

$MAIA @rustycat Very high quality post and worthy of an upvote.

User Image Doozio Posted - 3 hours ago

Chop chop huckleberries MAMA $maia it’s 🧠⏰

User Image LabPsycho Posted - 5 hours ago

$MAIA "Data from phase II clinical trials in which the DCR or CBR are reported suggest that DCR or CBR provides ambiguous information that likely exaggerates the anticancer activity of the therapy. The terms 'disease control' and 'clinical benefit' in the context of non-randomized trials are themselves disingenuous because neither tumor regression nor stable disease, defined without any consideration of duration of effect or reduction of symptoms appropriate for the specific patient population, are evidence of these endpoints in an individual patient." Doesnt matter, probably going up another 80% from here near term. https://pubmed.ncbi.nlm.nih.gov/21268434/

User Image Roycer1983 Posted - 16 hours ago

$MAIA $4mil added to market cap on Friday alone.

User Image SDW77 Posted - 19 hours ago

$MAIA

User Image insiderbuyingselling Posted - 19 hours ago

$MAIA new insider buying: 147492 shares. http://insiderbuyingselling.com/?t=MAIA

User Image Bakker123 Posted - 21 hours ago

$MAIA nice

User Image Rippinlips Posted - 21 hours ago

$MAIA As Johnny Cochrane used to say, ” If the insiders load, it will explode!”

User Image Smc14325 Posted - 22 hours ago

$MAIA if we could get even a million volume this things going to rocket.

User Image ItsJustWanna Posted - 22 hours ago

$MAIA amazing close here!

User Image Pharmbird Posted - 23 hours ago

$MAIA Sick call amigo. Legit one here I’ll be lurking ;)

User Image Rippinlips Posted - 23 hours ago

$MAIA @Stocks4thought how’s your rum punch and conch fritters?

User Image ItsJustWanna Posted - 1 day ago

$MAIA With the recent price action, it looks like we are getting very close to good news. Thoughts?

User Image DiferTrades Posted - 1 day ago

$MAIA winner!!!

User Image peapope Posted - 1 day ago

$MAIA going bananas now

User Image nediBeoJkcuF Posted - 1 day ago

$MAIA Boom I called 3.20s. I'm cool

User Image kubota2323 Posted - 1 day ago

$MAIA adding more.

User Image kubota2323 Posted - 1 day ago

$MAIA Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4 Smith Stan Director Apr 25 '24 Buy 2.03 147,492 299,409 1,005,060

User Image nediBeoJkcuF Posted - 1 day ago

$MAIA insiders going hamm

User Image nediBeoJkcuF Posted - 1 day ago

$MAIA More buying from insiders

User Image Kremm Posted - 1 day ago

$MAIA woah AH movement that’s new.

User Image nediBeoJkcuF Posted - 1 day ago

$MAIA If we blow out Keytruda 71% efficacy, Thio can easily top 7 billion in sales

User Image SDW77 Posted - 1 day ago

$MAIA

User Image kubota2323 Posted - 1 day ago

$MAIA excellent close. Fk off shorty.

User Image Babss1986 Posted - 1 day ago

$MAIA

User Image Vilvi Posted - 1 day ago

$MAIA I think my accumulation phase is over. I guess it's time to sit and watch :)

User Image nediBeoJkcuF Posted - 1 day ago

$MAIA 3.20s on deck

User Image mostlyzero Posted - 1 day ago

$MAIA very healthy movement today.

Analyst Ratings
Noble Capital Markets Outperform Feb 21, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Guerrero Ramiro Director Director May 18 Buy 2.47 1,200 2,964 312,672 05/22/23
Luput Cristian Director Director May 15 Buy 2.63 3,000 7,890 298,068 05/17/23
Vitoc Vlad Chief Executive Offi.. Chief Executive Officer Apr 28 Buy 2.50 4,000 10,000 809,121 05/01/23
MCGUIRE JOSEPH F Chief Financial Offi.. Chief Financial Officer Apr 27 Buy 2.25 4,400 9,900 9,400 04/28/23
Guerrero Ramiro Director Director Apr 27 Buy 2.25 8,500 19,125 311,472 04/28/23
Louie Ngar Yee Director Director Apr 27 Buy 2.25 48,000 108,000 976,584 04/28/23
Smith Stan Director Director Apr 27 Buy 2.25 133,300 299,925 686,628 04/28/23
Smith Stan Director Director Apr 20 Buy 3.74 10,000 37,400 553,328 04/21/23
Guerrero Ramiro Director Director Apr 18 Buy 4.17 1,263 5,267 302,972 04/19/23
Luput Cristian Director Director Apr 17 Buy 3.69 1,576 5,815 295,068 04/18/23
Luput Cristian Director Director Apr 13 Buy 3.6 1,424 5,126 293,492 04/17/23
Vitoc Vlad Chief Executive Offi.. Chief Executive Officer Apr 03 Buy 3.53 2,300 8,119 805,121 04/05/23
Vitoc Vlad Chief Executive Offi.. Chief Executive Officer Mar 30 Buy 3.45 1,700 5,865 802,821 04/03/23
Smith Stan Director Director Mar 24 Buy 3.49 938 3,274 543,328 03/28/23
Smith Stan Director Director Mar 22 Buy 3.31 3,320 10,989 542,390 03/24/23
Smith Stan Director Director Mar 20 Buy 3.23 5,742 18,547 539,070 03/22/23
Luput Cristian Director Director Mar 10 Buy 4.03 8,382 33,779 292,068 03/14/23
Guerrero Ramiro Director Director Mar 09 Buy 3.98 1,500 5,970 300,376 03/13/23
Smith Stan Director Director Mar 09 Buy 4.03 3,582 14,435 533,328 03/13/23
Luput Cristian Director Director Mar 08 Buy 4.1 2,741 11,238 283,686 03/10/23
Smith Stan Director Director Mar 07 Buy 4.22 5,037 21,256 529,746 03/09/23
Vitoc Vlad Chief Executive Offi.. Chief Executive Officer Mar 08 Buy 4.21 1,581 6,656 801,121 03/09/23
Luput Cristian Director Director Mar 06 Buy 4.24 2,215 9,392 280,945 03/08/23
Guerrero Ramiro Director Director Mar 06 Buy 4.25 1,352 5,746 298,876 03/08/23
Vitoc Vlad Chief Executive Offi.. Chief Executive Officer Mar 06 Buy 4.24 1,983 8,408 799,540 03/08/23
Smith Stan Director Director Mar 03 Buy 4.41 7,103 31,324 524,709 03/07/23
Vitoc Vlad Chief Executive Offi.. Chief Executive Officer Mar 02 Buy 4.45 2,443 10,871 797,557 03/06/23
Smith Stan Director Director Mar 01 Buy 4.45 221 983 517,606 03/03/23
Vitoc Vlad Chief Executive Offi.. Chief Executive Officer Feb 28 Buy 4.49 1,557 6,991 795,114 03/02/23
Smith Stan Director Director Feb 27 Buy 4.48 1,838 8,234 517,385 03/01/23
Smith Stan Director Director Feb 21 Buy 4.49 1,301 5,841 515,547 02/23/23
Vitoc Vlad Chief Executive Offi.. Chief Executive Officer Feb 17 Buy 4.25 73 310 793,557 02/22/23
Smith Stan Director Director Feb 16 Buy 4.25 137 582 514,246 02/21/23
Guerrero Ramiro Director Director Feb 16 Buy 4.25 60 255 297,524 02/21/23
Luput Cristian Director Director Feb 16 Buy 4.25 134 570 278,730 02/21/23
Vitoc Vlad Chief Executive Offi.. Chief Executive Officer Feb 15 Buy 4.25 20 85 793,484 02/17/23
Smith Stan Director Director Feb 14 Buy 4.25 208 884 514,109 02/16/23
Luput Cristian Director Director Feb 14 Buy 4.25 24 102 278,596 02/16/23
Vitoc Vlad Chief Executive Offi.. Chief Executive Officer Feb 10 Buy 4.24 343 1,454 793,464 02/14/23
Smith Stan Director Director Feb 10 Buy 4.25 337 1,432 513,901 02/14/23
Smith Stan Director Director Jan 25 Buy 4.25 236 1,003 513,564 01/27/23
Luput Cristian Director Director Jan 13 Buy 3.88 504 1,956 278,572 01/18/23
Vitoc Vlad Chief Executive Offi.. Chief Executive Officer Dec 30 Buy 3.57 2,734 9,760 791,855 01/04/23
Smith Stan Director Director Dec 29 Buy 3.5 1,971 6,898 513,328 01/03/23
Smith Stan Director Director Dec 27 Buy 3.4 1,870 6,358 511,357 12/29/22
Smith Stan Director Director Dec 22 Buy 3.4 1,712 5,821 509,487 12/27/22
Smith Stan Director Director Dec 20 Buy 3.48 4,447 15,476 507,775 12/22/22
Gryaznov Sergei Chief Scientific Off.. Chief Scientific Officer Dec 07 Option 1.83 10,000 18,300 44,511 12/08/22
Vitoc Vlad Chief Executive Offi.. Chief Executive Officer Aug 01 Buy 5 16,000 80,000 210,000 11/23/22
Guerrero Ramiro Director Director Sep 13 Buy 3.85 8,799 33,875 297,464 09/13/22